Signatory authority will remain with the review division, but OTBB staff will perform a primary review of some biosimilar labeling supplements. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
